Table 3.
Variable | Odds ratio | 95% CI | p value |
---|---|---|---|
| |||
Gender | |||
Male (vs. “female” as a reference group) | 0.88 | 0.57–1.37 | 0.573 |
| |||
Race/ethnicity | |||
White (vs. “other” as a reference group) | 1.76 | 1.08–2.84 | 0.022 |
| |||
Duration of illicit pharmaceutical opioid use (in years, continuous variable) | 1.06 | 0.95–1.18 | 0.304 |
| |||
Frequency of non-medical pharmaceutical opioid use | |||
1–2 days/week (vs. “less than 1 day/week” as a reference group) | 2.87 | 1.67–4.92 | <0.001 |
3 or more days/week (vs. “less than 1 day/week” as a reference group) | 4.96 | 2.58–9.54 | <0.001 |
| |||
Non-medical use of OxyContin | 1.76 | 1.04–2.97 | 0.034 |
| |||
Pharmaceutical opioid administration | |||
Snorting ( vs. “oral use” as a reference group) | 1.53 | 0.76–3.09 | 0.232 |
| |||
Reasons of use | |||
To get high and to self-medicate (vs. “self-medicate only” as a reference group) | 2.35 | 1.22–4.52 | 0.010 |
To get high only (vs. “self-medicate only” as a reference group) | 2.62 | 1.28–5.37 | 0.009 |
Hosmer-Lemeshow test: X2 =2.033, df=8, p=0.980*
The Hosmer-Lemeshow goodness-of-fit-statistic was used to assess if the model’s estimates fit the data at an acceptable level. Non-significant outcome (Hosmer-Lemeshow goodness-of-fit test statistic is greater than .05) indicates that the model prediction does not significantly differ from the observed, and thus the model has a good fit.